Company intelligence / Profile preview

Kariya Pharmaceuticals

Ownership: Private
Development stage: Phase 1

Overview

Kariya Pharmaceuticals is developing first-in-class dual incretin receptor co‑agonists to slow progression of neurodegenerative diseases. Their lead compound KP405 has shown efficacy in multiple animal models and demonstrated superiority over existing incretin therapies. The company is preparing for its first human trials targeting Parkinson's and Alzheimer's disease.

Therapeutic areas: Neurology
Modalities: Small molecules/peptides (dual incretin receptor co-agonists)Disease-modifying agents for neurodegeneration
Industry: Biotech

Drug pipeline

1 asset

KP405

Partnerships

BNC Korea Inc.: Strategic partnership for development/commercialization of KP405/KP404 in South Korea, Indonesia, Malaysia, Singapore, Thailand.

Beyond the preview

Go deeper on Kariya Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kariya Pharmaceuticals.

Explore the full profile